Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.50 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610499 | 0.92 | GRM2 (0.51) | GRM2GRM3ALDH1A1EPHX1HPGD | |
| SCHEMBL16610571 | 0.89 | GRM2 (0.51) | GRM2GRM3ALDH1A1EPHX1HPGD | |
| SCHEMBL16610929 | 0.88 | GRM2 (0.54) | GRM2GRM3ALDH1A1EPHX1HPGD | |
| SCHEMBL16613104 | 0.88 | GRM2 (0.54) | GRM2GRM3ALDH1A1EPHX1HPGD | |
| SCHEMBL19177419 | 0.88 | GRM2 (0.54) | GRM2GRM3ALDH1A1EPHX1HPGD | |
| SCHEMBL16610556 | 0.88 | GRM2 (0.54) | GRM2GRM3ALDH1A1EPHX1HPGD | |
| SCHEMBL16610461 | 0.88 | GRM2 (0.54) | GRM2GRM3ALDH1A1EPHX1HPGD | |
| SCHEMBL16610465 | 0.88 | GRM2 (0.52) | GRM2GRM3ALDH1A1HPGDTSHR | |
| SCHEMBL16610612 | 0.87 | GRM2 (0.50) | GRM2GRM3ALDH1A1EPHX1HPGD | |
| SCHEMBL16610498 | 0.86 | GRM2 (0.51) | GRM2GRM3ALDH1A1EPHX1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2857385-B1 | PRODRUG OF FLUORINE-CONTAINING AMINO ACID | TAISHO PHARMACEUTICAL CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-9428483-B2 | Prodrug of fluorine-containing amino acid | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2016-08-30 | — | — | US | disclosed |
| US-20150141669-A1 | PRODRUG OF FLUORINE-CONTAINING AMINO ACID | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857385-A1 | PRODRUG OF FLUORINE-CONTAINING AMINO ACID | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141669-A1 | PRODRUG OF FLUORINE-CONTAINING AMINO ACID | SLC1A2, SLC1A1, SLC1A3 | GRM2 9/4885GRM3 12/4885ALDH1A1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.